Stratec stock: Nine-month margin improves as sales decline
Published on 11/19/2026 at 00:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSMargin gains reshape the outlook
- Stratec's nine-month sales declined, while adjusted EBIT margin improved year over year.
- The company expects stable to slightly higher continuing-operations sales in 2026.
- The Diatron sale is intended to sharpen the group's focus and lift profitability.
Stratec reported its final results for the first nine months of 2026 on November 12. Consolidated sales fell 5.0% at constant currency to 164.9 million euros, while adjusted EBIT rose to 13.7 million euros and the adjusted EBIT margin increased to 8.3% from 7.3%. The figures were published in the company's quarterly statement.
Results balance weaker sales
Nominal sales declined 6.1% from the prior-year period. Operating cash flow improved to 39.4 million euros from negative 1.4 million euros, while the third-quarter adjusted EBIT margin reached 11.3%. A non-cash measurement effect of negative 44.1 million euros in the third quarter was linked to the sale of the Diatron Group.
Guidance focuses on core operations
For continuing operations, Stratec expects 2026 sales to remain stable to slightly higher on a constant-currency basis compared with pro forma 2025 sales of 223.5 million euros. The company forecasts an adjusted EBIT margin of 13.0% to 15.0% and investments in property, plant and equipment and intangible assets equal to 5.0% to 7.0% of sales.
Stratec signed an agreement on October 30 to sell Diatron MI to a consortium of Indian investors for a fixed purchase price of 10.0 million euros plus potential earn-out payments. Closing is expected in the fourth quarter of 2026. The business being sold is expected to contribute about 20.0 million euros in 2026 sales and negative 10.0 million euros in adjusted EBIT.
Stratec stock trades above Xetra close
Stratec stock traded at 27.88 euros on Lang & Schwarz at 23:00 CET on Wednesday, November 18, 1.94 percent above the Xetra close of Wednesday, November 18. The contrast between lower reported sales and stronger adjusted profitability leaves execution of the continuing-operations plan as the next key focus for investors.
Diagnostics systems remain central
Stratec develops and supplies automated systems for laboratory diagnostics, including platforms serving central laboratories as well as molecular and immunoassay applications. The company is based in Birkenfeld, Germany, and its continuing operations are being positioned around higher-margin diagnostic systems after the Diatron divestment.
Stratec company facts
- Company: Stratec SE
- ISIN: DE000STRA555
- Xetra ticker: SBS.DE
- Lang & Schwarz price: 27.88 euros at 23:00 CET on November 18, 2026
- Change versus Xetra close: 1.94% above the November 18, 2026 close at 27.35 euros
- Adjusted EBIT margin, nine months 2026: 8.3%
The German stock market environment provides the broader setting for Stratec's trading.
More news and analyses on Stratec stock are available here.
